It was identified as a potential drug target for Alzheimer’s disease, Down syndrome, and TBC1D24-associated epilepsy, while also loss-of-function mutations in Synj1 are associated with epilepsy and Parkinson’s disease. The gene discussed is TBC1D24; the disease is early-onset autosomal dominant Alzheimer disease.